Press Releases

• • All Categories
  • C. difficile
  • Chikungunya
  • COVID-19
  • DUKORAL®
  • IXIARO®
  • Lyme Disease
  • Uncategorized

Filter By Year 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

March 3, 2009

VIVALIS AND FORT DODGE ANIMAL HEALTH SIGN A COMMERCIAL LICENSE AGREEMENT TO USE THE EB66®CELL LINE FOR VIRAL VACCINES PRODUCTION.

February 17, 2009

VIVALIS AND BOEHRINGER INGELHEIM ANIMAL HEALTH SIGN A RESEARCH LICENSE AGREEMENT, WITH AN OPTION TO ENTER INTO A COMMERCIAL LICENSE AGREEMENT TO USE EB66® PLATFORM FOR VETERINARY VACCINES PRODUCTION

February 9, 2009

VIVALIS ACHIEVES SIGNIFICANT MILESTONES IN THE DEVELOPMENT OF HUMAN FLU VACCINES BASED ON THE EB66® CELL LINE

February 3, 2009

NOVAVAX AND VIVALIS SIGN A RESEARCH LICENSE AGREEMENT TO USE THE EB66® CELL LINE FOR THE PRODUCTION OF VIRUS LIKE PARTICULE BASED VACCINES. Rockville

January 27, 2009

2008 revenue multiplied by 5 to €5.4 million Net cash at December 31, 2008: €22.7 million, up €1.3 from the first half 4 years of financial visibility

January 21, 2009

VIVALIS AND INNATE PHARMA SIGN A COLLABORATION AND COMMERCIAL LICENSE AGREEMENT TO DEVELOP INNATE’S NOVEL MONOCLONAL ANTIBODY, TO BE MANUFACTURED WITH VIVALIS’ EB66® PLATFORM, FOR RARE CUTANEOUS CANCERS

January 13, 2009

PURSUIT OF ROBUST COMMERCIAL EXPANSION IN 2009 TARGET: 6 TO 7 NEW LICENSES INCLUDING TWO COMMERCIAL LICENSES

December 17, 2008

VIVALIS AND KAKETSUKEN SIGN TWO COMMERCIAL LICENSE AGREEMENTS TO USE THE EBx® PLATFORM FOR THE PRODUCTION OF HUMAN AND VETERINARY VIRAL VACCINES.

December 10, 2008

VIVALIS SECURES IMPORTANT PATENTS COVERING THE USE OF EB66® PLATFORM TO PRODUCE RECOMBINANT VACCINES

November 4, 2008

PRESENTATION AT THE RODMAN & RENSHAW HEALTHCARE CONFERENCE IN NEW YORK OF NOVEMBER 10-11, 2008